Funding
Our current and past funding sources
Agency | Duration | Name |
---|---|---|
European Research Council | 2024-2030 | Functional cartography of intestinal host-microbiome interactions (CartoHostBug) |
Deutsche Forschungsgemeinschaft | 2023-present | Establishing a knowledge graph community in biomedical science |
Deutsche Forschungsgemeinschaft | 2022-present | Deciphering molecular circuits of cardiac remodeling and dysfunction via an integrative reverse approach (B10) |
Deutsche Forschungsgemeinschaft | 2022-present | INFrastructurefor Biobanking, Data Management and Bioinformatics (INF) |
Deutsche Forschungsgemeinschaft | 2022-present | MacTrac – Tracking spatio-temporal trajectories of macrophage subtypes in inflammatory demyelination |
Deutsche Forschungsgemeinschaft | 2022-present | Single-cell and spatial mapping of human diabetic cardiomyopathy |
European Commission | 2021-2026 | DECIDER: Improved clinical decisions via integrating multiple data levels to overcome chemotherapy resistance in high-grade serous ovarian cancer |
Sanofi | 2021-2021 | Analysis of essentiality in cancer using CRISPR-Cas9 screenings |
Bundesministerium für Bildung und Forschung | 2021-2023 | LiSyM-Krebs: Mechanism-based Multiscale Model to Dissect the Tipping Point from Liver Cirrhosis to Hepatocellular Carcinoma |
Bundesministerium für Bildung und Forschung | 2021-2024 | DeepSC2: Deep learning for single-cell genomics in cancer |
German Research Foundation | 2021-present | Dissecting IgA nephropathy via integration of multi-omics data |
Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg | 2020-2022 | BioDATEN : Bioinformatics DATa Environment |
Bundesministerium für Bildung und Forschung | 2020-2022 | MSCare: A Systems Medicine Approach to Stratification of Cancer Recurrence |
European Commission | 2020-2024 | StrategyCKD: System omics to unravel the gut-kidney axis in Chronic Kidney Disease |
European Commission | 2020-2022 | PerMedCoE: HPC Center of Excellence in Personalised Medicine |
GlaxoSmithKline | 2020-2022 | Analysis of multi-omics and spatial transcriptomics data |
German Research Foundation | 2020-present | Single cell resolution of human chronic kidney disease for precision medicine in nephrology |
H2020 Health | 2019-2022 | individualizedPaediatricCure: Cloud-based virtual-patient models for precision paediatric oncology |
Ministry of Education and Science | 2019-2022 | LaMarcK: Longitudinal Multiomics Characterization of disease using prior Knowledge |
Klaus-Tschira Stiftung | 2019-2021 | Informatics for Life |
German Research Foundation | 2018-present | Validating microfluidics-based personalized cancer therapy in mouse models |
European Commission | 2017-2021 | TransQST: Translational quantitative systems toxicology to improve the understanding of the safety of medicines |
OncoSignature/Acrivon | 2017-2018 | Analysis of mass spectrometry proteomics and drug treatment |
BMBF German Ministery of Education and Research | 2016-2019 | SYS4MS: Personalizing health care in Multiple Sclerosis using sytems medicine tools |
BMBF German Ministery of Education and Research | 2016-2020 | LiSym: Liver systems medicine |
National Cancer Institute | 2016-2018 | CPTAC DREAM Challenge |
Research Executive Agency | 2016-2018 | PrECISE: Personalized engine for Cancer integrative study and evaluation |
Research Executive Agency | 2015-2018 | SyMBioSys : Systematic Models for Biological Systems Engineering Training Network |
Bayer AG | 2015-2019 | Joint Research Center for Computational Biomedicine |
Center for Therapeutic Target Validation | 2014-2016 | Novel Target Identification Through Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cancer Cell Lines |
Center for Therapeutic Target Validation | 2014-2016 | Target identification and validation using pathway activities derived from functional genomics data |
Research Executive Agency | 2013-2014 | CombiMS: a novel drug discovery method based on systems biology: combination therapy and biomarkers for Multiple Sclerosis |
Medical Research Council | 2012-2014 | Understanding drug mode of action via statistical integration of functional genomic studies and literature-derived signalling networks |
Research Executive Agency | 2012-2015 | BioPreDyn: New Bioinformatics Methods and Tools for Data-Driven Predictive Dynamic Modelling in Biotechnological Applications |
Sanofi | 2011-2012 | Analysis of mass spectrometry phosphoproteomics data in the context of insulin signal processing and functional alterations thereof |